中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
14期
1879-1880
,共2页
前S1抗%HBV DNA%HBV M
前S1抗%HBV DNA%HBV M
전S1항%HBV DNA%HBV M
pre-S1 Ag%HBV DNA%HBV M
目的 验证前S1抗原在HBV组合检测中的价值.方法 收集门诊同步检测HBV DNA、HBV M、ALT/AST的288份血清,应用ELISA方法检测前S1抗原.结果 288份血清中男175份,女113份,中位年龄36.89岁,均为CHB.其中pre-S1Ag(+)197份(68.4%),HBV DNA＞5.0E+2copy/ml 161份(55.9%),eAg(+)71份(24.6%),eAg(-)186份(64.58%),ALT/AST＞42/50 u/ml、ALT＞40 u/ml 64份(22.2%,AST＞50 u/ml 60份(20.8%).分P-S1Ag(+)和P-S1Ag(-)两组,在P-S1Ag(+)组中HBV DNA＞界值124例占62.9%,HBeAg阴性118份占59.8%占优势:分析HBV DNA阳性率和病毒血症水平P-S1Ag(+)和P-S1 Ag(-)在低于界值时各为35.2%和63.6%,在低于103copy/ml时各为56.9%和81.7%,在105-108 copy/ml时各为33%和14.3%;两组差异有统计学意义.结论 P-S1Ag阳性在慢性乙肝中eAg阴性预疗病毒复制,协助诊断预后.
目的 驗證前S1抗原在HBV組閤檢測中的價值.方法 收集門診同步檢測HBV DNA、HBV M、ALT/AST的288份血清,應用ELISA方法檢測前S1抗原.結果 288份血清中男175份,女113份,中位年齡36.89歲,均為CHB.其中pre-S1Ag(+)197份(68.4%),HBV DNA＞5.0E+2copy/ml 161份(55.9%),eAg(+)71份(24.6%),eAg(-)186份(64.58%),ALT/AST＞42/50 u/ml、ALT＞40 u/ml 64份(22.2%,AST＞50 u/ml 60份(20.8%).分P-S1Ag(+)和P-S1Ag(-)兩組,在P-S1Ag(+)組中HBV DNA＞界值124例佔62.9%,HBeAg陰性118份佔59.8%佔優勢:分析HBV DNA暘性率和病毒血癥水平P-S1Ag(+)和P-S1 Ag(-)在低于界值時各為35.2%和63.6%,在低于103copy/ml時各為56.9%和81.7%,在105-108 copy/ml時各為33%和14.3%;兩組差異有統計學意義.結論 P-S1Ag暘性在慢性乙肝中eAg陰性預療病毒複製,協助診斷預後.
목적 험증전S1항원재HBV조합검측중적개치.방법 수집문진동보검측HBV DNA、HBV M、ALT/AST적288빈혈청,응용ELISA방법검측전S1항원.결과 288빈혈청중남175빈,녀113빈,중위년령36.89세,균위CHB.기중pre-S1Ag(+)197빈(68.4%),HBV DNA＞5.0E+2copy/ml 161빈(55.9%),eAg(+)71빈(24.6%),eAg(-)186빈(64.58%),ALT/AST＞42/50 u/ml、ALT＞40 u/ml 64빈(22.2%,AST＞50 u/ml 60빈(20.8%).분P-S1Ag(+)화P-S1Ag(-)량조,재P-S1Ag(+)조중HBV DNA＞계치124례점62.9%,HBeAg음성118빈점59.8%점우세:분석HBV DNA양성솔화병독혈증수평P-S1Ag(+)화P-S1 Ag(-)재저우계치시각위35.2%화63.6%,재저우103copy/ml시각위56.9%화81.7%,재105-108 copy/ml시각위33%화14.3%;량조차이유통계학의의.결론 P-S1Ag양성재만성을간중eAg음성예료병독복제,협조진단예후.
Objective To evaluate the value of pre-S1 Ag in combined detection of hepatitis B virus. Methods 288 patients' serums with chronicity type B hepatitis (CHB)were collected when they had been detected with HBV-DNA,HBVM or ALT/AST,and then ELISA assay were applied to detect pre-S1Ag. Results A total of 288 patients ,including 175 males and 113 females( their meso-age is 36.89 years old) were recruited into this study. 161 patients were pre-S1 Ag positive(68.4%), 197 patients' HBV DNA contents exceeded 5.0E + 2 copy/ml(55.9%) ,71patients were H BeAg positive (24.6%), 186 patients were HBeAg negative (64.58%). The rate of 64 patients' ALT and AST exceeded 0. 84, and their' ALT exceeded 40 u/ml ( 22. 2% ). 60 patients' AST exceeded 50 u/ml (20. 8% ). These patients were divided into pre-S1 Ag positive group and pre-S1 Ag group. In pre-S1 Ag positive group, 124 patients' HBV DNA contents exceeded 5.0E + 2 copy/ml( 62.9% ), 118 patients were HBeAg negative (59.8%). When HBV DNA content was less than 5.0E+2 copy/ml,pre-S1 Ag positive rate was 35.2% and pre-S1 Ag negative rate was 63.6%. when HBV DNA content was less than 5.0E + 3 copy/ml, pre-S1 Ag positive rate was 56.9% and pre-S1 Ag negative rate was 81.7%. When HBV DNA content exceeded 5.0E + 5 copy/ml but less than 5.0E + 8 copy/ml ,pre-S1 Ag positive rate was 33% and pre-S1 Ag negative rate was 14.3% ,so two groups had significant difference. Conclusion Pre-S1 Ag positive and HBeAg negative in the CHB patients serums signify virus replication,and it can help us decide prognosis.
